Age of diabetes onset: glycaemic control and hypoglycaemia benefit with new insulin glargine 300 U/mL in T2DM (#255)

2:00 PM

Stephen Twigg

Switching from twice-daily basal insulin to once-daily new insulin glargine 300 U/mL (Gla-300): an analysis in people with T2DM (EDITION 1 and 2) (#256)

2:00 PM

Michael d'Emden

Real-world experience with Dapagliflozin in people with type-2 diabetes living in Western Sydney: Beneficial impact on biomarkers and reasons for discontinuation. (#257)

2:00 PM

Tristan Nguyen

A one-year prospective experience using Optifast^® vs glucagon-like peptide-1 analogues in obese adult patients with type 2 diabetes (#258)

2:00 PM

Ramy H Bishay

Effect of exenatide in combination with insulin in patients with type 2 diabetes mellitus on insulin requirement, weight and glycaemic control – prospective audit on local clinical protocol (follow-up result) (#259)

2:00 PM

Ning Ning Choo

Response to exenatide over 2 years in very obese type 2 diabetics. (#260)

2:00 PM

Richard Burnet

Decreased stomal output in response to liraglutide: a case study (#261)

2:00 PM

Yee -Ming Melody YM Cheung

Factors associated with insulin-induced weight gain in an Australian type 2 diabetes outpatient clinic. (#262)

2:00 PM

John M Wentworth

Prescription of hypoglycaemic medications in people with renal impairment and type 2 diabetes attending Australian general practice (#263)

2:00 PM

Jo-Anne E Manski-Nankervis

Improving the Transition of Care of Inpatients with Type 2 Diabetes (#264)

2:00 PM

Felicity Pyrlis

Fournier’s syndrome: a life threatening complication of SGLT2 inhibition in poorly controlled diabetes mellitus (#265)

2:00 PM

Wenlin Cecilia Chi

The changing management of type 2 diabetes - metabolic/bariatric surgery in Western Sydney (#266)

2:00 PM

Carolyn Jameson

Efficacy of an intensive and integrated team-based model of care for severely obese patients with type 2 diabetes in a public hospital setting   (#267)

2:00 PM

Evan Atlantis

Factors Associated with Insulin Adherence among Patients with Type 2 Diabetes: The MOSAIc Study (#268)

2:00 PM

Helen Barraclough

Silent Diabetic Ketoacidosis: Sodium-Glucose Cotransporter 2 Inhibitor-Induced Euglycaemic Diabetic Ketoacidosis (#269)

2:00 PM

Shamil D Cooray